
|Articles|September 1, 2002
- Psychiatric Times Vol 19 No 9
- Volume 19
- Issue 9
Father Fear
When she asks me to massage the ache in her knuckles,
Advertisement
When she asks me to massage
the ache in her knuckles,
I recall women I have touched
whose hands twisted
like apricot limbs
in their search for light.
I've never asked how
they hold a fork, play piano,
or stroke a lover's hair,
and when I rub my daughter's bones
with the soft pads of my fingertips
it is like wishing on a magic lamp:
Please, not Lupus,
not steroids or morphine or wheelchairs.
I've seen apricots in my orchard
blossom too soon,
so fragrant in early April
killed by hard frost in May.
Articles in this issue
about 24 years ago
End of Storyabout 24 years ago
Supreme Court Decision Raises New Ethical Questions for Psychiatryabout 24 years ago
Help for Psychiatrists Who Lose a Patient to Suicideabout 24 years ago
Antidepressants Versus Placebos: Meaningful Advantages Are Lackingabout 24 years ago
Optimizing ADHD Treatmentabout 24 years ago
Depressive Disorders in Adolescents: Challenges in Diagnosisabout 24 years ago
Behavioral Issues in Pediatric Epilepsyabout 24 years ago
Catatonia in Adolescents and Childrenabout 24 years ago
Small Effects Are Not Trivial From a Public Health PerspectiveAdvertisement
Related to this article

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.

Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.

Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
5

